Global Bacterial Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2017
No. of pages: 800
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Bacterial Partnering 2010 to 2017 provides the full collection of Bacterial disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Bacterial partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Bacterial partnering agreement structure

Bacterial partnering contract documents

Top Bacterial deals by value

Most active Bacterial dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.

The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Bacterial dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Bacterial dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Bacterial deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Bacterial dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Bacterial deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Bacterial partnering deals by specific Bacterial target announced since 2010. The chapter is organized by specific Bacterial therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Bacterial partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Bacterial partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Bacterial technologies and products.

Report scope

Global Bacterial Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Bacterial trends and structure of deals entered into by leading companies worldwide.

Global Bacterial Partnering 2010 to 2017 includes:

Trends in Bacterial dealmaking in the biopharma industry since 2010

Analysis of Bacterial deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Bacterial deal contract documents

Comprehensive access to over 3500 Bacterial deal records

The leading Bacterial deals by value since 2010

Most active Bacterial dealmakers since 2010

The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

In Global Bacterial Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Bacterial Partnering 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise bacterial rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Key benefits

Global Bacterial Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Bacterial deal trends since 2010

Access Bacterial deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Bacterial partner companies

Comprehensive access to over 750 links to actual Bacterial deals entered into by the world's biopharma companies

Indepth review of Bacterial deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Bacterial opportunities

Uncover companies actively partnering Bacterial opportunities

Global Bacterial Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Bacterial dealmaking
2.1. Introduction
2.2. Bacterial partnering over the years
2.3. Bacterial partnering by deal type
2.4. Bacterial partnering by industry sector
2.5. Bacterial partnering by stage of development
2.6. Bacterial partnering by technology type
2.7. Bacterial partnering by therapeutic indication

Chapter 3 -Financial deal terms for Bacterial partnering
3.1. Introduction
3.2. Disclosed financials terms for Bacterial partnering
3.3. Bacterial partnering headline values
3.4. Bacterial deal upfront payments
3.5. Bacterial deal milestone payments
3.6. Bacterial royalty rates

Chapter 4 - Leading Bacterial deals and dealmakers
4.1. Introduction
4.2. Most active in Bacterial partnering
4.3. List of most active dealmakers in Bacterial
4.4. Top Bacterial deals by value

Chapter 5 - Bacterial contract document directory
5.1. Introduction
5.2. Bacterial partnering deals where contract document available

Chapter 6 - Bacterial dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Bacterial therapeutic target

Appendices

Appendix 1 - Directory of Bacterial deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Bacterial deals by deal type 2010 to 2017
Appendix 3 - Directory of Bacterial deals by stage of development 2010 to 2017
Appendix 4 - Directory of Bacterial deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Bacterial partnering since 2010
Figure 2: Bacterial partnering by deal type since 2010
Figure 3: Bacterial partnering by industry sector since 2010
Figure 4: Bacterial partnering by stage of development since 2010
Figure 5: Bacterial partnering by technology type since 2010
Figure 6: Bacterial partnering by indication since 2010
Figure 7: Bacterial deals with a headline value
Figure 8: Bacterial deals with upfront payment values
Figure 9: Bacterial deals with milestone payment
Figure 10: Bacterial deals with royalty rates
Figure 11: Active Bacterial dealmaking activity- 2010 to 2017
Figure 12: Top Bacterial deals by value since 2010
  • United States Tigecycline Market Report 2017
    Published: 22-Nov-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Tige......
  • Global Tigecycline Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Tigecycline for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • Global and Regional Cephalosporin Market Research Report 2017
    Published: 15-Nov-2017        Price: US 3500 Onwards        Pages: 180
    Summary Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium" Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - First Generation - Second Generation......
  • United States Cefprozil Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States Cefprozil market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Cefpro......
  • Q Fever - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 36
    Q Fever - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2017, provides an overview of the Q Fever (Infectious Disease) pipeline landscape. Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscl......
  • Escherichia coli Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 171
    Escherichia coli Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into cont......
  • Tularaemia - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 72
    Tularaemia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape. Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conju......
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 84
    Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape. Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomyci......
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 369
    Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape. MRSA infections that are acquired by persons who have n......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs